Senolytics will prove more valuable for non-cancer aging than for cancer itself

Senolytics were developed to clear cancer-promoting senescent cells. But their greatest impact may be in treating frailty, cognitive decline, and metabolic dysfunction—not oncology.

The reasoning is counterintuitive: cancer is already treated by surgery, radiation, and cytotoxic chemotherapy. But age-related functional decline has no existing cures. Senolytics could fill that gap.